Why the study?
Monotherapy with a potent P2Y12 inhibitor after short-term DAPT is an attractive strategy to balance ischaemia and bleeding after DES for ACS, but its efficacy and safety needed evaluation.
Does ticagrelor monotherapy after short-term DAPT reduce bleeding without increasing ischemic events compared to 12-month DAPT in ACS patients undergoing DES implantation?
Does ticagrelor monotherapy after short-term DAPT reduce bleeding without increasing ischemic events compared to 12-month DAPT in ACS patients undergoing DES implantation?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“These novel and compelling data challenge the conventional paradigm of using dual antiplatelet therapy in all patients after an acute coronary syndrome. The net clinical benefit provided by ticagrelor monotherapy offers clinicians a reassuring alternative to long-term dual antiplatelet therapy in these high-risk patients.”
“We are very honored to have collaborated with our colleagues in Korea, to pool individual patient data on two similar trials, and now have some definitive answers in how to treat patients with acute coronary syndromes. This strategy of short (3 months) dual antiplatelet therapy (ticagrelor plus aspirin) followed by ticagrelor monotherapy is associated with less bleeding without any compromise in ischemic events.”
“While T-PASS and TICO trials were exclusively done in South Korean centers, TWILIGHT trial was conducted at 187 sites across 11 countries. The event rate in T-PASS study is much lower than in prior studies (PLATO, ISAR-REACT5, etc.) perhaps suggesting lower-risk patients were included in this trial.... while the findings of this study are providing reassurance on shortening DAPT period in selected patients, we recommend caution on generalization of the findings of this study to all patients with ACS and across different DES platforms.”
In ACS patients undergoing DES implantation, ticagrelor monotherapy after short-term DAPT reduces major bleeding without increasing ischemic events compared to standard 12-month DAPT.
BACKGROUND AND AIMS: In patients with acute coronary syndrome (ACS), dual antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor is recommended for 12 months after drug-eluting stent (DES) implantation. Monotherapy with a potent P2Y12 inhibitor after short-term DAPT is an attractive option to better balance the risks of ischaemia and bleeding. Therefore, this study evaluated the efficacy and safety of ticagrelor monotherapy after short-term DAPT, especially in patients with ACS. METHODS: Electronic databases were searched from inception to 11 November 2023, and for the primary analysis, individual patient data were pooled from the relevant randomized clinical trials comparing ticagrelor monotherapy after short-term (≤3 months) DAPT with ticagrelor-based 12-month DAPT, exclusively in ACS patients undergoing DES implantation. The co-primary endpoints were ischaemic endpoint (composite of all-cause death, myocardial infarction, or stroke) and bleeding endpoint [Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding] at 1 year. RESULTS: Individual patient data from two randomized clinical trials including 5906 ACS patients were analysed. At 1 year, the primary ischaemic endpoint did not differ between the ticagrelor monotherapy and ticagrelor-based DAPT groups [1.9% vs. 2.5%; adjusted hazard ratio (HR) 0.79; 95% confidence interval (CI) 0.56-1.13; P = .194]. The incidence of the primary bleeding endpoint was lower in the ticagrelor monotherapy group (2.4% vs. 4.5%; adjusted HR 0.54; 95% CI 0.40-0.72; P < .001). The results were consistent in a secondary aggregate data meta-analysis including the ACS subgroup of additional randomized clinical trials which enrolled patients with ACS as well as chronic coronary syndrome. CONCLUSIONS: In ACS patients undergoing DES implantation, ticagrelor monotherapy after short-term DAPT was associated with less major bleeding without a concomitant increase in ischaemic events compared with ticagrelor-based 12-month DAPT. STUDY REGISTRATION: PROSPERO (ID: CRD42023476470).
No takes yet. Share an insight, caveat, or question.
Lee et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: